Charles River Laboratories Intl. (NYSE:CRL) issued an update on its FY19 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $6.40-6.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.48.
Shares of CRL opened at $125.45 on Friday. Charles River Laboratories Intl. has a 52 week low of $103.00 and a 52 week high of $149.07. The stock has a market capitalization of $6.12 billion, a P/E ratio of 20.80, a P/E/G ratio of 1.62 and a beta of 0.99. The company has a current ratio of 1.63, a quick ratio of 1.39 and a debt-to-equity ratio of 1.10.
Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Tuesday, May 7th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.38 by $0.02. The firm had revenue of $604.57 million for the quarter, compared to analyst estimates of $587.65 million. Charles River Laboratories Intl. had a net margin of 9.63% and a return on equity of 23.03%. The business’s revenue was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.29 EPS. Equities analysts expect that Charles River Laboratories Intl. will post 6.47 earnings per share for the current year.
In other Charles River Laboratories Intl. news, EVP Joseph W. Laplume sold 5,522 shares of Charles River Laboratories Intl. stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $137.61, for a total value of $759,882.42. Following the sale, the executive vice president now owns 16,325 shares of the company’s stock, valued at $2,246,483.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William D. Barbo sold 4,905 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $125.16, for a total transaction of $613,909.80. Following the completion of the sale, the insider now directly owns 25,859 shares in the company, valued at approximately $3,236,512.44. The disclosure for this sale can be found here. Insiders have sold 14,569 shares of company stock worth $1,928,205 over the last three months. 1.80% of the stock is owned by insiders.
Charles River Laboratories Intl. Company Profile
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Further Reading: Economic Reports
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.